GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Germany’s Merck KGaA for the rights to a next-generation immunotherapy.
Source:: Reuters – Business News
Newswire
- [ January 7, 2025 ] Immuneering (NASDAQ: IMRX) Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms Newsmakers
- [ January 7, 2025 ] MultiSensorAI (NASDAQ:MSAI) Announces Next Steps in Leadership Optimization Plan as it Prepares for Rapid Growth Newsmakers
- [ January 7, 2025 ] AEye (NASDAQ: LIDR) Provides Update on Apollo 4Sight’s Record-Breaking Behind-the-Windshield Performance Newsmakers
- [ January 7, 2025 ] XTI Aerospace (NASDAQ: XTIA) Completes General Familiarization Presentation of TriFan 600 Vertical Lift Crossover Airplane (VLCA) to FAA Aerospace & Defense
- [ January 7, 2025 ] Singing Machine (NASDAQ: RIME) to Showcase Industry Leading Karaoke Microphone at CES 2025 Newsmakers
- [ January 6, 2025 ] Arbe (NASDAQ: ARBE) Collaborates with NVIDIA to Enhance Radar-Based Free Space Mapping and AI-Driven Capabilities Newsmakers
- [ January 6, 2025 ] Fubo (NYSE: FUBO) and Disney’s Hulu + Live TV Virtual MVPD Businesses to Combine Newsmakers
- [ January 6, 2025 ] SciSparc (NASDAQ: SPRC)-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment Newsmakers
- [ January 2, 2025 ] N2OFF, Inc. (NASDAQ: NITO) Announces Its JV with Soltera Renewable Energy Ltd Obtained an Approval of 111 MWp Solar PV Project in Meltz Germany Newsmakers
- [ January 2, 2025 ] Expion360 (NASDAQ: XPON) to Begin Shipping e360 Home Energy Storage Solutions to Integration Partner Wellspring Solar Uncategorized
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.